The United Kingdom and the United States have secured a key commercial pact that will ensure no levies on UK drug exports going into the American market.
The Terms of the Deal
Under the terms of the agreement, the UK has pledged to increase spending on medicines through the NHS. This commitment ensures that import taxes on these crucial products will be held at nothing for a timeframe of three years.
This deal is in response to previous threats to dramatically increase import taxes on patented pharmaceutical products, with increases mentioned as high as double the cost.
"This arrangement between the UK reinforces the worldwide climate for new treatments and establishes long-overdue equity to U.S.–U.K. pharmaceutical trade," an announcement said.
Economic Importance
Pharmaceuticals are one of the the United Kingdom's most significant exports to the US, which is clearly the biggest buyer for major British pharmaceutical firms.
Statistics indicate that in the year prior to September, the UK shipped medicines worth over eleven billion pounds to the US. This value made up a significant portion of all goods exports in that span.
"This guarantee protects jobs, increases funding and paves the way for the UK to become a global hub for biotech and pharma," the Business and Trade Secretary remarked.
Detailed UK Commitments
The pact involves several notable pledges from the UK:
- Revised Affordability Limit: The UK will increase the price threshold at which it judges new medicines to be too expensive by 25%.
- Boosted Medicine Funding: There is a goal to raise total NHS spending on drugs from 0.3% of Gross Domestic Product to 0.6 percent over the next decade.
- Rebate Cap: The percentage drug companies must pay back to the NHS to control costs will be limited at 15%. In the past, repayments topped 20%.
Recent Tensions
The deal takes place against a protracted dispute between the pharmaceutical industry and the UK government over medicine costs and regulatory access.
These tensions were intensified by arguments that American consumers were paying significantly more for the equivalent treatments than people in the other developed nations.
In recent months, several significant drug company projects in the UK have been halted or cancelled, while multi-billion-dollar investments have been announced toward projects in the United States.
The Science Minister acknowledged that the NHS must increase expenditure on treatments, noting that its expenditure on drugs had decreased as a percentage of its resources over the past decade.
